Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

NCT00025896 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease
Glycogen Storage Disease Type II
Acid Maltase Deficiency Disease
Glycogenosis 2

Interventions

DRUG: recombinant human acid alpha-glucosidase (rhGAA)

Sponsor

Genzyme, a Sanofi Company